Biocon has received USFDA approval for Pebrilzo (pertuzumab-qcay), a biosimilar of breast cancer drug Perjeta. It is Biocon’s fifth oncology biosimilar approved in the US, and a settlement with Genentech fixes the earliest US launch for 2028.

The Approval and What Pebrilzo Treats

Biocon Limited announced on Monday, November 16, 2026, that the US Food and Drug Administration (USFDA) has approved Pebrilzo, a biosimilar of Perjeta (pertuzumab). The company disclosed the approval in an exchange filing. Biocon shares trade on BSE under code 532523 and on NSE under the symbol BIOCON.

Pebrilzo is a monoclonal antibody that blocks HER2 receptors on cancer cells. It is indicated, together with trastuzumab and chemotherapy, for early-stage and metastatic HER2-positive breast cancer. A biosimilar is a biologic medicine that is highly similar to an already approved reference product.

Why HER2-Positive Breast Cancer Matters

HER2-positive breast cancer is a form of the disease in which cancer cells carry a protein called HER2 that promotes growth. Pertuzumab is used alongside trastuzumab and chemotherapy to treat it. Biosimilars are developed to offer lower-cost alternatives once patents and exclusivity on the original biologic allow, which is why the legal settlement and the regulatory approval both matter to the commercial outlook.

Biocon’s Oncology Biosimilars Cleared by the USFDA

Pebrilzo is the fifth oncology biosimilar from Biocon to receive USFDA clearance. The existing four are:

  1. Ogivri (trastuzumab-dkst)
  2. Jobevne (bevacizumab-nwgd)
  3. Fulphila (pegfilgrastim-jmdb)
  4. Aukelso (denosumab-kyqq)

Biocon’s oncology pipeline also includes proposed biosimilars to trastuzumab with hyaluronidase, nivolumab and pembrolizumab, covering HER2-directed therapy and immuno-oncology.

Launch Timeline Under the Genentech Settlement

Approval does not mean immediate sales. Biocon announced a global patent settlement and licence agreement with Genentech, part of the Roche group, on October 14, 2026. On the same day, a US district court in New Jersey dismissed the pending patent litigation over the pertuzumab biosimilar without prejudice. The remaining settlement terms are confidential.

MarketEarliest licensed launch
United StatesThird quarter of 2028
European Union and United KingdomFirst quarter of 2027
Other marketsBetween 2026 and 2028, with earlier entry possible in certain cases

All launches remain subject to regulatory approval in each market. In Europe, the European Medicines Agency’s CHMP issued a positive opinion in September 2026 recommending marketing authorisation for Pebrilzo.

The Size of the Market Biocon is Targeting

Perjeta generated global sales of about 2.97 billion Swiss francs in 2025, according to Roche’s financial disclosures. That figure shows the scale of the originator product, though it does not indicate how much of that revenue a biosimilar would capture.

Biocon has also secured a long-term pertuzumab supply contract in Brazil. For the company, the settlement gives clearer visibility on launch dates, which helps in planning manufacturing, supply arrangements and commercial partnerships.

Competition and Commercial Uncertainty

Biocon will not be alone in the pertuzumab biosimilar space. The USFDA approved Poherdy, developed by Shanghai Henlius Biologics, as the first interchangeable biosimilar to Perjeta in November 2025. Genentech’s US litigation over that product ended in a confidential settlement earlier in 2026.

Roche’s subcutaneous combination therapy Phesgo could also affect demand for standalone pertuzumab products. The revenue a biosimilar maker earns depends on pricing discounts, competition and how quickly hospitals and healthcare providers adopt lower-cost alternatives.

Background on Biocon’s Biosimilars Business

Biocon’s biosimilars are developed and sold through its subsidiary Biocon Biologics. When Jobevne won USFDA approval in April 2025, the company described it as its seventh biosimilar approved in the US. At that time, Biocon Biologics had commercialised nine biosimilars from a pipeline of 20 products across the US, Europe, Australia, Canada and Japan. Pebrilzo adds another oncology product to that list.

Also Read: Jimmy Tata Backs Tata Sons Listing While Noel Tata Opposes It and RBI Rule Still Applies

Company Commentary

Shreehas Tambe, Biocon’s CEO and managing director, described Pebrilzo as strengthening the company’s anti-cancer portfolio. He said it advances Biocon’s aim of expanding access to high-quality and affordable biologic medicines, and noted that HER2-positive breast cancer places a heavy financial burden on patients and families.

What to Watch Next

The approval removes one regulatory step, but the commercial benefit lies some way ahead. The first licensed launches are scheduled for the EU and UK in the first quarter of 2027, and for the US in the third quarter of 2028. In the meantime, investors tracking Biocon will watch the final European marketing authorisation decision, further regulatory clearances in other markets, and progress on the pembrolizumab and nivolumab biosimilars in the pipeline.